Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations

Những quyển sách tương tự

• The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China
  Bằng: Xu, Jianlin, et al.
  Được phát hành: (2016)
• EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
  Bằng: Xu, Jianlin, et al.
  Được phát hành: (2016)
• Corrigendum: EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
  Bằng: Xu, Jianlin, et al.
  Được phát hành: (2016)
• Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis
  Bằng: Lou, Yuqing, et al.
  Được phát hành: (2021)
• Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors combined with chemotherapy in first‐line treatment in an advanced non‐small cell lung cancer patient with EGFR sensitive mutation
  Bằng: Huang, Aimi, et al.
  Được phát hành: (2016)